RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - RUOLO DEGLI ORMONI IPOFISARI NELLE NEOPLASIE.
• 2 - Avanzamenti nella diagnosi molecolare e nel trattamento dei tumori neuroendocrini
• 3 - Studio delle alterazioni biomolecolari e dei profili di espressione genica nel carcinoma colorettale e pancreatico: identificazione di possibili elementi prognostici e bersagli terapeutici nel sistema degli eicosanoidi e dei cannabinoidi.
• 4 - Fisiopatologia,clinica e terapia dei tumori corticosurrenalici
• 5 - Sviluppo e progressione del carcinoma epatocellulare: meccanismi molecolari ed implicazioni terapeutiche
• 6 - Marcatori molecolari nel carcinoma del cavo orale e loro impiego nella diagnosi precoce, nella prognosi e nella risposta ai farmaci antiblastici.
• 7 - Ruolo dell'ATP extracellulare nella patogenesi delle neoplasie tiroidee e nella modulazione di vecchi e nuovi markers di malattia
• 8 - Valutazione della risposta tumorale con parametri biologici, immunologici e di imaging funzionale
• 9 - Il colangiocarcinoma: approccio terapeutico basato su nuove acquisizioni di biologia cellulare e molecolare.
• 10 - I carcinomi in situ aggressivi della mammella. Caratteristiche strutturali, geniche e prospettive terapeutiche.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • ONCOLOGIA MEDICA
  • ANATOMIA PATOLOGICA
  • ENDOCRINOLOGIA
  • CHIRURGIA GENERALE
  • CHIRURGIA TORACICA

Classificazione brevettuale

• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Veneto

Bibliografia

1. Modlin IM, Sandor A. An analysis of 8305 carcinoid tumors. Cancer 1997;79:813-29.
2. Hage R, Brutel de la Riviere A, Seldenrijk CA, Van den Bosch JMM. Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol 2003;10:697-704.
3. Ducrocq X, Thomas P, Massard G, Barsotti P, Giudicelli R, Fuentes P et al. Operative risk and prognostic factors of typical bronchial carcinoid tumors. Ann Thorac Surg 1998;65:1410-14.
4. Rea F, Binda R, Spreafico G, Calabrò F, Bonavina L, Cipriani A, Di Vittorio G, Fassina A, Sartori F. Bronchial carcinoids: a review of 60 patients. Ann Thorac Surg 1989;47:1410-4.
5. Filosso PL, Rena O, Donati G, et al. Bronchial carcinoid tumors: surgical management and long-term outcome. J Thorac Cardiovasc Surg 2002;123: 303-9.
6. Sutedja TG, Schreurs AJ, Vanderschueren RG, Kwa B, vd Werf TS, Postmus PE. Bronchoscopic therapy in patients with intraluminal typical bronchial carcinoid. Chest 1995;107:556-8.
7. Cavaliere S, Foccoli P, Toninelli C. Curative Bronchoscopic laser therapy for surgically resectable tracheobronchial tumors: Personal experience. J Bronch 2002;9(2):90-95.
8. Mezzetti M, Raveglia F, Panigalli T, Giuliani L, et al. Assessment of oucomes in typical and atypical carcinoids according to latest WHO classification. Ann Thorac Surg 2003;76:1838-42.
9. Obuch M, Doppman JL, Strader DB et al: Imaging for pancreatic endocrine tumors localization: recent advances. in Mignon M.-Jenses RT(eds) Front Gastroint Res 23: 268-281 (1995)
10. Palazzo L, Roseau G, Salmeron M: Endoscopic ultrasonography in the preoperative localization of endocrine pancreatic tumors. Endoscopy 24 (suppl 1): 350-353 (1992)
11. Lebtahi R, Cadiot G, Sarda L, et al: Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med 38: 853-58 (1997)
12. Krenning EP, Kwekkboom DJ, Oei HY, de Jong RJB, Dop FJ, Reubi JC, Lamberts SWJ. Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results. Ann NY Acad Sci 733: 416-24, (1994)
13. Pasquali C, Rubello D, Sperti C,et al.: Neuroendocrine tumor imaging: can 18-FDG Positron Emission Tomography detect tumors with poor prognosis and aggressive behavior? World J Surg 22: 588-592 (1998).
14. Pasquali C., Sperti C., Lunardi C., Scappin S., Chierichetti F., Liessi G., Pedrazzoli S.: La tomografia ad emissione di positroni con fluorodesossiglucosio nei tumori neuroendocrini gastro-entero-pancreatici: ruolo diagnostico e implicazioni prognostiche. Suppl Tumori 4 (3): S68-S71, (2005).
15. Adams S, Baum RP, Hertel A, Schumm-Drager PM, Usadel KH, Hor G: Metabolic (PET) and receptor (SPET) imaging of well- and less well-differntiated tumours: comparison with the expression of the Ki-67 antigen. Nucl Med Commun 19: 641-647 (1998).
16. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA:Neuroendocrine Hepatic Metastases Does Aggressive Management Improve Survival? Ann Surg 241:776–785, (2005)
17. Turner HE, Harris AL, Melmed S, Wass JAH: Angiogenesis in endocrine tumors. Endocrine Review 24(5): 600-632, 2003
18. Folkman J: Clinical applications of research on angiogenesis. N Engl J Med 333: 1757-1763, 1995
19. La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C: Localization of vascular endothelial growth factor and its receptors in digestive endocrine tumors: correlation with microvessel density and clinicopathologic features. Human Pathology 34: 18-27, 2003
20. Solcia E, Kloppel G & Sobin LH (eds). Histological typing of endocrine tumours. 2000, Springer verlag, New York.
21. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC (eds). Tumours of the lung, pleura, thymus and heart. WHO classification of tumours. 2004, Lyon.
22. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, Allasia C, Bonnier P, Charpin C. Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol. 2004 Feb;3(2):176-83.
23. Mineo TC, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B, Tonini G. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 2004 Jun;57(6):591-7.
24. Weidner N. The importance of tumor angiogenesis: the evidence continues to grow. Am J Clin Pathol. 2004 Nov;122(5):675-7.
25. Cherrington JM, Strawn LM, Shawver LK. New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. Adv Cancer Res. 2000;79:1-38.
26. Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control. 2002 Mar-Apr;9(2 Suppl):36-44.
27. Stepieri H.M., Kolomecki K, Pasieka Z, Komorowskj J, Stepien T, Kuzdak K: Angiogenesis of endocrine gland tumours – new molecular targets in diagnostics and therapy. European Journal of Endocrinology 146, 143-151, 2002.
28. La Rosa S, Uccella S, Finzi G, Albarello L, Sessa F, Capella C.: Localization of Vascular Endoctelial Growth Factor and its Receptors in Digestive Endocrine Tumours: Correlation with Microvessel Density and Clinicopathologic Features. Human Pathology 34, 1, 18-27, 2003.
29. Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G, Albini A.: Somatostatin Inhibits Tumor Angiogenesis and Growth via Somatostatin Receptor.3-Mediated Regulation of Endothelial Nitric Oxide Synthase and Mitogen-Activated Protein Kinase Activities. Endocrinology 144, (4) 1574-1584, 2003.
30. Turner HE, Harris AL, Melmed S, Wass JAH.: Angiogenesis in endocrine tumors. Endocrine Reviews 24, (5) , 600-632, 2003.
31. Dasgupta P.: Somatostatin analogues:Multiple roles in cellular proliferation, neoplasia and angiogenesis. Pharmacology and Therapeutics 102, 61-85, 2004.
32. Adams RL, Adams IP, Lindow SW, Zhong W and Atkin SL: Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. British Journal of Cancer 92, 1493-1498, 2005
33. Aparicio T, Ducreux M, Baudin E, Sabourin JC, De Baere T, Mitry E, Schlumberger M, Rougier P. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer. 2001;37:1014-9.
34. Bertherat J, Tenenbaum F, Perlemoine K, Videau C, Alberini JL, Richard B, Dousset B, Bertagna X, Epelbaum J. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. Clin Endocrinol Metab 2003;88:5353-60
35. Bondanelli M, Ambrosio MR, Zatelli MC, Cavazzini L, Al Jandali Rifa'y L, degli Uberti EC. Regression of liver metastases of occult carcinoid tumor with slow release lanreotide therapy. 2005, World J Gastroenterol 11:2041-4.
36. de Herder WW, Hofland LJ, van der Lely AJ, et al. Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocr Relat Cancer 2003;10:451-8.
37. de Herder WW, Lamberts SW. Somatostatin and somatostatin analogues: diagnostic and therapeutic uses. Curr Opin Oncol. 2002;14:53-7.
38. Kimura N, Pilichowska M, Date F, Kimura I, Schindler M. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res. 1999;5:3483-7.
39. Kulaksiz H, Eissele R, Rossler D, Schulz S, Hollt V, Cetin Y, Arnold R. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002;50:52-60.
40. Janson ET, Stridsberg M, Gobl A, Westlin JE, Oberg K. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies. Cancer Res. 1998 Jun 1;58(11):2375-8.

Parole Chiave

CARCINIODI BRONCHIALI, TUMORI NEUROENDOCRINI GASTROENTERO PANCREATICI, NEOANGIOGENESI, RECETTORI DELLA SOMATOSTATINA